ReCor Medical Receives CE Mark for its Generation 2, Ultrasound-based PARADISE™ Renal Denervation System

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCor Medical announced today that it has received CE mark for its next-generation PARADISE system, a minimally invasive 6Fr over-the-wire (OTW) ultrasound device for treating resistant high blood pressure. Additionally, the treatment parameters of Gen 2 have been further enhanced to reduce energy delivery to 30 seconds by maximizing cooling of the endothelium and efficiently treating the nerves circumferentially. A live case is planned Friday, January 25, 2013, at the ‘LINC’ (Leipzig Interventional Course) meeting in Leipzig, Germany.

“The Gen 2 O-T-W PARADISE system is designed to offer optimal non-invasive ultrasound therapy for resistant hypertension patients to reduce resistant high blood pressure”

The Gen 1 PARADISE system previously received CE mark just over one year ago. The Gen 2 PARADISE system considerably enhances efficiency while making the procedure easier and quicker. It is the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency (RF), energy.

“The Gen 2 O-T-W PARADISE system is designed to offer optimal non-invasive ultrasound therapy for resistant hypertension patients to reduce resistant high blood pressure," said Professor Marc Sapoval, Chair of the Cardiovascular Radiology Department at Hôpital Européen Georges-Pompidou, Paris, France. "The new features of Gen 2, including an over-the-wire 6Fr device and a quicker procedure, offers patients a superior treatment option to reduce their blood pressure".

“The benefit of ReCor’s ultrasound approach is three-fold,” explained Mano Iyer, CEO of ReCor Medical. “Firstly, PARADISE is designed to penetrate much deeper into the tissue, up to 8 millimeters; secondly, PARADISE delivers heat circumferentially, to target all of the renal nerves in one location; thirdly, PARADISE does this while simultaneously cooling the artery wall’s surface to protect the vessel.

“Our unique approach is in stark contrast to RF, which is limited in its depth of penetration to just a few millimeters, due to inconsistent arterial wall contact, as well as its inability to heat circumferentially in any given location,” said Iyer. “In addition, RF technologies generate unnecessary heating at the level of the arterial wall. Data presented at TCT 2012 concluded that renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscores the PARADISE ultrasound advantage.”

About ReCor Medical, Inc.

ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology. ReCor is backed by European and U.S. investors, including Sofinnova Partners, one of the largest life science investors in Europe. The Company’s PARADISE™ ultrasound catheter, which is CE-marked, is designed with the aim to allow complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency ablation catheter. For more information about ReCor Medical, please visit www.recormedical.com.

NOTE: PARADISE™ is approved for sale in Europe; it is not approved for sale or investigational use in the United States.